

BIOMARIN PHARMACEUTICAL INC

Form 4

February 10, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
SPIEGELMAN DANIEL K

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
105 DIGITAL DRIVE
(Street)

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2013

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
EVP, Chief Financial Officer

NOVATO, CA 94949

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount or Price | | |
| Common Stock | 03/18/2013 | 03/18/2013 | A ⁽¹⁾ | 7 | A \$ 61.4829 | 68,683 | D |
| Common Stock | 03/18/2013 | 03/18/2013 | A ⁽¹⁾ | 7 | A \$ 61.3814 | 68,690 | D |
| Common Stock | 03/20/2013 | 03/20/2013 | A ⁽¹⁾ | 5 | A \$ 61.988 | 68,695 | D |
| Common Stock | 03/20/2013 | 03/20/2013 | A ⁽¹⁾ | 4 | A \$ 61.4325 | 68,699 | D |
| Common Stock | 06/19/2013 | 06/19/2013 | A ⁽¹⁾ | 9 | A \$ 58.5678 | 68,708 | D |

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

| | | | | | | | | |
|--------------|------------|------------|---------------------------|----|---|------------|--------|---|
| Common Stock | 06/19/2013 | 06/19/2013 | <u>A⁽¹⁾</u> | 9 | A | \$ 58.8478 | 68,717 | D |
| Common Stock | 09/10/2013 | 09/10/2013 | <u>A⁽¹⁾</u> | 8 | A | \$ 70.0583 | 68,725 | D |
| Common Stock | 09/10/2013 | 09/10/2013 | <u>A⁽¹⁾</u> | 7 | A | \$ 70.3029 | 68,732 | D |
| Common Stock | 10/04/2013 | 10/04/2013 | <u>A⁽¹⁾</u> | 5 | A | \$ 74.074 | 68,737 | D |
| Common Stock | 10/07/2013 | 10/07/2013 | <u>A⁽¹⁾</u> | 6 | A | \$ 74.8383 | 68,743 | D |
| Common Stock | 10/30/2013 | 10/30/2013 | <u>A⁽¹⁾</u> | 4 | A | \$ 66.475 | 68,747 | D |
| Common Stock | 10/30/2013 | 10/30/2013 | <u>A⁽¹⁾</u> | 5 | A | \$ 65.75 | 68,752 | D |
| Common Stock | 11/20/2013 | 11/20/2013 | <u>A⁽¹⁾</u> | 8 | A | \$ 65.8863 | 68,760 | D |
| Common Stock | 03/05/2014 | 03/05/2014 | <u>S⁽¹⁾⁽²⁾</u> | 12 | D | \$ 82.9258 | 68,748 | D |
| Common Stock | 05/02/2014 | 05/02/2014 | <u>S⁽¹⁾</u> | 3 | D | \$ 58.0233 | 68,745 | D |
| Common Stock | 05/02/2014 | 05/02/2014 | <u>S⁽¹⁾</u> | 8 | D | \$ 58.78 | 68,737 | D |
| Common Stock | 08/06/2014 | 08/06/2014 | <u>A⁽¹⁾</u> | 7 | A | \$ 62.1671 | 68,744 | D |
| Common Stock | 08/06/2014 | 08/06/2014 | <u>A⁽¹⁾</u> | 7 | A | \$ 62.1771 | 68,751 | D |
| Common Stock | 09/03/2014 | 09/03/2014 | <u>S⁽¹⁾⁽²⁾</u> | 9 | D | \$ 69.8289 | 68,742 | D |
| Common Stock | 09/03/2014 | 09/03/2014 | <u>S⁽¹⁾⁽²⁾</u> | 9 | D | \$ 69.7011 | 68,733 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene |
|--|------------------------------------|--------------------------------------|--|--------------------------------|-------------------------|--|--|--|------------------------|
|--|------------------------------------|--------------------------------------|--|--------------------------------|-------------------------|--|--|--|------------------------|

| | | | |
|------------------------|---|--------------------|---|
| Derivative Security | Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | (Instr. 3 and 4) | Own Follo Repo Trans (Instr |
| | Code V (A) (D) Date Exercisable | Expiration Date | Title Amount or Number of Shares |

Reporting Owners

| Reporting Owner Name / Address | Relationships |
|--|---|
| | Director 10% Owner Officer Other |
| SPIEGELMAN DANIEL K 105 DIGITAL DRIVE NOVATO, CA 94949 | EVP, Chief Financial Officer |

Signatures

| | |
|---|------------|
| /s/ Laura Randall Woodhead, Attorney-in-Fact | 02/10/2015 |
| __Signature of Reporting Person | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Inadvertent transaction not directed by the reporting person through a broker-administered investment pool.
Some of the transactions executed as reported herein resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"). The Reporting Person has made arrangements with the Issuer to disgorge short swing profits realized to the Issuer, and upon settlement, the Reporting Person will have discharged in full any obligation under Section 16(b) with respect to the reported transactions.
- (2)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.